CXCL8 and obstructive sleep apnea syndrome: It is possible that blocking the IL-8 function with antagonists to reduce the intermittent hypoxia-induced chemotactic migration of monocytes, an early inflammatory process of atherosclerosis, could be one potential strategy to reduce the progression of atherosclerosis in patients with OSA.